Jiangsu Hengrui Pharmaceuticals Announces HRS‑2430 Injection Approval for Clinical Trials
China‑listed Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous...
National Health Commission’s Negative Behavior List for Medical Staff Internet‑Based Health Science Popularization (Trial)
The National Health Commission (NHC) announced on 7 November 2025 a “Negative Behavior List for Medical Staff...
Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal
Novo Nordisk A/S (NYSE: NVO) confirmed today that it will not pursue an increased offer...
Aureka Biotechnologies Closes Multi‑Million‑Dollar Series A – Generative Antibody Platform Gains 5Y Capital & Qiming Backing
Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of...
Zhaoke Ophthalmology Indonesia Distribution Deal – BRIMOCHOL PF Eyes on Market Expansion
China‑listed Zhaoke Ophthalmology Ltd. (HKG: 6622) announced a new distribution and supply agreement with Indonesia’s...
Shanghai‑Boehringer Ingelheim MOU Launches Stroke Prevention Initiative – Strengthening China Health 2030
During the 8th China International Import Expo (CIIE), the Shanghai Medical Association (SMA) and Boehringer Ingelheim...
Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative
Boehringer Ingelheim announced at the 8th China International Import Expo (CIIE) that it has signed...
Zai Lab Q3 2025 Revenue Up 13% YoY to $115.4 M, Led by Nuzyra and Xacduo; Zejula Slows
Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third‑quarter 2025 financial results, reporting total...
Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders
In a high‑profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:...
NHSA Pilot AI Review Accelerates Full‑Process Medical Insurance Assessment in 7 Chinese Provinces
The National Healthcare Security Administration (NHSA) has announced a three‑phase, AI‑powered review pilot covering Beijing,...
US FDA’s CNPV Fast‑Track Program Expands to 15 Drugs, Cutting Review Time to Months
The Commissioner’s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two‑batch...
Sichuan Biokin Launches on HKEX, Raises HK$3.3 B in $389/Share Offering – A Milestone for China’s Biotech
China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its successful initial public offering (IPO)...
LifeTech Scientific Secures NMPA Approval for G‑Branch TAAA Stent‑Graft System
LifeTech Scientific Corporation (HKG: 1302) announced that China’s National Medical Products Administration (NMPA) has granted...
Viatris Posts Q3 2025 Revenue Dip, Highlights Emerging‑Market Branded Growth and Aculys Pharma Acquisition
U.S.‑based Viatris Inc. (NASDAQ: VTRS) released its third‑quarter 2025 earnings, showing a 2 % year‑over‑year (YOY)...
Humanwell Healthcare Secures NMPA Approval to Launch First Fixed‑Dose Combination for Pulmonary Arterial Hypertension
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its investigational compound HWH217 has received...
Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) announced a historic agreement with the...
Johnson & Johnson Launches ETHICON 4000 3D Laparoscopic Stapler in China
Johnson & Johnson (J&J, NYSE: JNJ) announced today the commercial rollout of its ETHICON 4000 laparoscopic stapler...
BeOne Medicines Posts $1.4 B Q3 2025 Revenue, Driven by BRUKINSA Momentum
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released its third‑quarter 2025 financial results, reporting...
CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAAI Meeting
China‑based CStone Pharmaceuticals (HKG: 2616) announced that the pre‑clinical results for its bispecific biologic CS2015...
AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal
AmacaThera, the hydrogel‑technology biotech incubated by Viva BioInnovator (VBI), announced an exclusive worldwide licensing agreement...